1. Home
  2. SEVN vs SGMT Comparison

SEVN vs SGMT Comparison

Compare SEVN & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seven Hills Realty Trust

SEVN

Seven Hills Realty Trust

HOLD

Current Price

$7.46

Market Cap

167.9M

Sector

Real Estate

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$11.09

Market Cap

676.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEVN
SGMT
Founded
1986
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
167.9M
676.3M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
SEVN
SGMT
Price
$7.46
$11.09
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
$10.50
$26.13
AVG Volume (30 Days)
137.1K
865.8K
Earning Date
04-28-2026
05-14-2026
Dividend Yield
13.90%
N/A
EPS Growth
N/A
N/A
EPS
0.19
N/A
Revenue
$29,383,000.00
$2,000,000.00
Revenue This Year
$27.75
N/A
Revenue Next Year
$4.06
N/A
P/E Ratio
$38.58
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.26
$4.50
52 Week High
$10.90
$11.45

Technical Indicators

Market Signals
Indicator
SEVN
SGMT
Relative Strength Index (RSI) 42.97 61.34
Support Level $7.38 $6.60
Resistance Level $7.84 $11.30
Average True Range (ATR) 0.12 0.55
MACD 0.01 -0.07
Stochastic Oscillator 42.86 77.98

Price Performance

Historical Comparison
SEVN
SGMT

About SEVN Seven Hills Realty Trust

Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: